Key points are not available for this paper at this time.
The pharmaceutical market has undergone radical changes, including markedly increased prices for rare-disease drugs. The revenue generated by such products raises questions about whether the Orphan Drug Act should be reformed to better align with the needs of patients.
Sarpatwari et al. (Wed,) studied this question.